TY - JOUR
T1 - D-Cycloserine for Treatment Nonresponders With Obsessive-Compulsive Disorder
T2 - A Case Report
AU - Norberg, Melissa M.
AU - Gilliam, Christina M.
AU - Villavicencio, Anna
AU - Pearlson, Godfrey D.
AU - Tolin, David F.
PY - 2012/5
Y1 - 2012/5
N2 - Despite being the most effective treatment available, as many as one third of patients who receive exposure and response prevention (ERP) for obsessive-compulsive disorder (OCD) do not initially respond to treatment. Recent research suggests that the n-methyl d-aspartate (NMDA) receptor partial agonist D-Cycloserine (DCS) may speed up the course of ERP for OCD rather than enhance it. Thus, it is unclear whether DCS would benefit patients who have proven nonresponsive to ERP and serotonin reuptake inhibitors. The present study evaluated the ability of DCS to enhance ERP for 2 patients with OCD who previously had failed to show adequate response to treatment using time-series analysis. Both patients experienced greater reductions with DCS augmented ERP than they did with prior treatment; however, 1 patient relapsed by the 1-month follow-up. DCS augmented ERP might be an effective method for boosting outcomes in individuals who do not readily respond to ERP.
AB - Despite being the most effective treatment available, as many as one third of patients who receive exposure and response prevention (ERP) for obsessive-compulsive disorder (OCD) do not initially respond to treatment. Recent research suggests that the n-methyl d-aspartate (NMDA) receptor partial agonist D-Cycloserine (DCS) may speed up the course of ERP for OCD rather than enhance it. Thus, it is unclear whether DCS would benefit patients who have proven nonresponsive to ERP and serotonin reuptake inhibitors. The present study evaluated the ability of DCS to enhance ERP for 2 patients with OCD who previously had failed to show adequate response to treatment using time-series analysis. Both patients experienced greater reductions with DCS augmented ERP than they did with prior treatment; however, 1 patient relapsed by the 1-month follow-up. DCS augmented ERP might be an effective method for boosting outcomes in individuals who do not readily respond to ERP.
KW - Behavior therapy
KW - D-Cycloserine
KW - Exposure and response prevention
KW - Obsessive-compulsive disorder
KW - Treatment nonresponder
UR - http://www.scopus.com/inward/record.url?scp=84858446664&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858446664&partnerID=8YFLogxK
U2 - 10.1016/j.cbpra.2011.05.002
DO - 10.1016/j.cbpra.2011.05.002
M3 - Article
AN - SCOPUS:84858446664
SN - 1077-7229
VL - 19
SP - 338
EP - 345
JO - Cognitive and Behavioral Practice
JF - Cognitive and Behavioral Practice
IS - 2
ER -